CA125 Response: Can it Replace the Traditional Response Criteria in Ovarian Cancer?

Abstract

CA125 is well established as an accurate and reliable means of monitoring response to treatment and confirming relapse in ovarian cancer patients. Its role in follow-up after initial treatment is less certain and the subject of a current clinical trial. Measuring response with computerized tomography scans is futile in the majority of patients, as disease is often nonmeasurable at presentation, e.g., ascites or peritoneal deposits, or all measurable disease has been removed at the time of surgery. Serial changes in CA125 can be used as a reliable indicator of disease response or progression so that patients can be classified as responding or progressing according to either standard or CA125 criteria. These precise definitions are currently being prospectively validated in conjunction with the new response evaluation criteria in solid tumor response guidelines and are being incorporated into all future clinical trials. The

Cancer diagnosis using proteomic patterns

“…Thirdly, it may be that the presence of a single, definitive biomarker for a particular histological condition, such as human chorionic gonadotropin for pregnancy, is the exception rather than the rule [9,10]. Indeed, many clinical tests that rely on single diagnostic biomarkers, such as cancerantigen (CA)-125 for ovarian cancer [11] and prostate specific antigen (PSA) for prostate cancer [12], possess positive predictive values (PPV) that are generally quite low.…”

Clinical Significance of Biomarkers in Ovarian Cancer, Prostate Cancer, Colorectal Cancer

“…После-довательное снижение уровней маркера в процессе те-рапии свидетельствует об ответе на лечение, в то время как рост показателей маркера или сохранение начально-го уровня говорит о низкой эффективной терапии [27]. У большинства пациенток, получающих адъювантное лечение по поводу III-IV стадий РЯ, отмечается нормали-зация уровня СА125 к 4-му циклу ХТ [28,29].…”

Over Tümörleri̇nde Tümör Beli̇rteçleri̇ Ve Kli̇ni̇k Önemleri̇

“…E Ep pi it te el ly ya al l O Ov ve er r K Ka an ns se er ri i 1 1a a. . C CA A--1 12 25 5 CA-125, 200 KD ağırlığında, çölemik epitel derivatiflerinden salgılanan bir glikoproteindir (3). OC 125 monoklonal antikoru kullanılarak serumda radyoimmunoassay ile tanınabilmektedir.…”

“…CA-125 yüksekliğini yorumlayarak nüksün gerçek zamanlamasını yapmak güçtür (29). Hastaların %70'inde, CA-125 yükseldikten sonraki ilk 4 ayda nüks olur.…”

“…Medical Research Council/European Organization for Research and Treatment of Cancer (MRC/EORTC) çalışması birinci-sıra kemoterapi sonrası komplet remisyondaki over kanserli hastalarda, CA-125 takibinin değerini ortaya koyacaktır. Bu hastalar, CA-125'te iki katına yükselme saptandığında (CA-125>30 U/ml'den sonra) randomize edilerek bir gruba 4 hafta içinde erken tedavi başlanmakta , diğer gruba ise klinik relaps saptandığında tedavi başlanmaktadır (29). Bir değer belirteç "tissue polypeptide antigen" (TPA) sensivitesi, ileri evre over tümörlerinde ve hücresel diferansiyasyonun artması ile yükselmek-tedir (31).…”